芪苈强心胶囊联合左西孟旦治疗射血分数保留型心力衰竭患者的临床疗效观察

Clinical Effect of Qili Qiangxin Capsule Combined with Levosimendan in the Treatment of Heart Failure with Preserved Ejection Fraction

摘要: 目的：探析对射血分数保留型心力衰竭患者应用芪苈强心胶囊联合左西孟旦治疗效果。方法：将本院2021年1月~2022年6月间收治84例射血分数保留型心力衰竭患者纳入研究对象，遵循随机方式将患者分为对照组、观察组，n = 42，对照组用左西孟旦治疗，观察组用芪苈强心胶囊联合左西孟旦治疗。从心功能、并发症方面评价芪苈强心胶囊联合左西孟旦临床应用价值。结果：治疗后观察组患者左室收缩末期内径(LVESD)、左室舒张末期内径(LVEDD)数据低于对照组，有统计学意义(P < 0.05)。观察组患者治疗后的动脉血气指标包括PaO2 (79.53 ± 4.10) mmHg、PaCO2 (33.15 ± 1.63) mmHg、SaO2 (93.88 ± 2.81)%改善情况明显优于对照组，两组比较差异显著(P < 0.05)。结论：对射血分数保留型心衰患者用芪苈强心胶囊联合左西孟旦治疗可以改善心衰症状及指标，安全性高，值得临床推广。

Abstract: Objective: To explore the therapeutic effect of Qili Qiangxin capsule combined with Levosimendan in patients with heart failure with preserved ejection fraction. Methods: A total of 84 patients with heart failure with preserved ejection fraction admitted to our hospital from January 2021 to June 2022 were included in the study. The patients were randomly divided into control group and ob-servation group, n = 42. The control group was treated with Levosimendan, and the observation group was treated with Qili Qiangxin capsule combined with Levosimendan. To evaluate the clinical application value of Qili Qiangxin capsule combined with Levosimendan from the aspects of cardiac function and complications. Results: After treatment, the data of left ventricular end-systolic diam-eter (LVESD) and left ventricular end-diastolic diameter (LVEDD) in the observation group were lower than those in the control group, with statistical significance (P < 0.05). The improvement of arterial blood gas indexes including PaO2 (79.53 ± 4.10) mmHg, PaCO2 (33.15 ± 1.63) mmHg, SaO2 (93.88 ± 2.81)% in the observation group after treatment was significantly better than that in the control group, and the difference between the two groups was significant (P < 0.05). Conclusion: Qili Qiangxin capsule combined with Levosimendan in the treatment of heart failure patients with pre-served ejection fraction can improve the symptoms and indicators of heart failure, with high safety, which is worthy of clinical promotion.